Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
